Professor Andrey Nikolaevych Belousov graduated from Kharkiv Medical Institute in 1988. He has held a Doctor of Medicine degree in Anesthesiology and Intensive Care since 2004. He is the author of the world’s first clinically approved and officially registered nanotechnology-based drugs (1995) used in medical practice.The title dissertation:“Extracorporal hemocorrection using magnet-controlled sorbent in intensive therapy of intoxication syndromes in patients with hepatopancreatoduodenales diseases” (2004). Author a new medicine products – nanotechnology preparations based on magnetite nanoparticles (Fe3O4 ) of the size 6-12 nm: the peroral form - Micromage-B (the biologically active additive officially registration in Ukraine); Magnet-controlled sorbent brand of MCS-B for extracorporal detoxication of biological liquids (officially registration in Ukraine and was allowed for medical practice); NanoBiocorrector for intravenous application – ICNB (intracorporal nanosorbent). Andrey Belousov is author new method of extracorporal hemocorrection using magnet-controlled sorbent (MCS-B). Author a new program (PHUAS) for estimation degree the severity of the patient. The published more 340 scientific works. He has got 8 patents for the invention. Author of the scientific film which focuses on the elaboration of artificial liver device and the development of a new direction in medicine – Nanotechnology. Andrey Belousov was awarded Medical Diploma of Europe “An Honorary Scholar Europe” and R. Koch medal for the scientific achievements, development of a new direction in medicine and elaboration of new method of treatment by means preparations of nanotechnology in 2008. At now Andrey Belousov - the Head of Laboratory Applied Nanotechnologies, DM, Professor of Department Anaesthesiology, Intensive Care and Paediatric Anaesthesiology of Kharkiv National Medical University, Ukraine. His research interests include nanomedicine, detoxification technologies, critical care pharmacology, and blood rheology correction. He continues to lead multidisciplinary research on the clinical application of nanostructured materials in medicine, contributing to the advancement of personalized and non-invasive therapies.